Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

141. Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: A Randomized Clinical Trial.

Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: A Randomized Clinical Trial. IMPORTANCE: Observational studies have reported that statin use may be associated with improved outcomes of various infections. Ventilator-associated pneumonia (VAP) is the most common infection in the intensive care unit (ICU) and is associated with substantial mortality. OBJECTIVE: To determine whether statin therapy can decrease day-28 mortality in patients with VAP. DESIGN (...) ventilation and Sequential Organ Failure Assessment (SOFA) scores on days 3, 7, and 14. RESULTS: The study was stopped for futility at the first scheduled interim analysis after enrollment of 300 patients, of whom all but 7% in the simvastatin group and 11% in the placebo group were naive to statin therapy at ICU admission. Day-28 mortality was not lower in the simvastatin group (21.2% [95% CI, 15.4% to 28.6%) than in the placebo group (15.2% [95% CI, 10.2% to 22.1%]; P = .10; hazard ratio, 1.45 [95% CI, 0.83

JAMA2013

142. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular (...) Diagnostics. Bibliographic details McConnachie A, Walker A, Robertson M, Marchbank L, Peacock J, Packard CJ, Cobbe SM, Ford I. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal 2014; 35(5): 290-298 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Cardiovascular Diseases /economics /prevention & Cost-Benefit Analysis; Health Resources

NHS Economic Evaluation Database.2013

143. Is it safe to use statins in a patient with hepatitis C virus (HCV) infection?

Is it safe to use statins in a patient with hepatitis C virus (HCV) infection? Is it safe to use statins in a patient with hepatitis C virus (HCV) infection? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Is it safe to use statins in a patient with hepatitis C virus (HCV) infection? View/ Open Date 2013-04 Format (...) Metadata Abstract Treatment with statins appears safe in patients with compensated chronic HCV infection (SOR: C, disease-oriented outcomes). No data are available on the safe use of statins in patients with acute HCV infection. URI Part of Part of Citation Evidence Based Practice 16(4): 12. Collections hosted by hosted by

Evidence Based Practice 2013

144. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study 23839541 2014 02 03 2014 09 26 2016 10 19 1522-9645 35 5 2014 Feb European heart journal Eur. Heart J. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. 290-8 10.1093/eurheartj/eht232 To assess (...) the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). Six thousand five hundred and ninety-five participants aged 45-54 years were randomized to 5 years treatment with pravastatin (40 mg) or placebo. Linkage to routinely collected health records extended follow-up for secondary healthcare resource utilization to 15 years. The following

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

145. Statins and the risk of interstitial lung disease: a cohort study

Statins and the risk of interstitial lung disease: a cohort study 23299962 2013 03 08 2013 07 08 2013 03 08 1468-3296 68 4 2013 Apr Thorax Thorax Statins and the risk of interstitial lung disease: a cohort study. 361-4 10.1136/thoraxjnl-2012-201823 Case reports have suggested that the use of statins may be associated with an increase in the risk of interstitial lung disease (ILD). Within a large cohort of users of respiratory medications identified in the Quebec health administrative databases (...) during 1990-2005, we carried out a nested case-control analysis of the relationship between statins and the risk of ILD as defined by specialist visits or hospitalisations. The cohort included over 1.4 million patients, of which 6665 possible or probable cases of ILD were identified during follow-up. These were compared with 26 660 controls matched for age, gender and calendar time. After adjustment for confounders and comorbid conditions, there was no association between current use of statins and

EvidenceUpdates2013

146. High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect

High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect 23674398 2013 06 26 2013 09 25 2015 11 19 1524-4539 127 25 2013 Jun 25 Circulation Circulation High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. 2485-93 10.1161/CIRCULATIONAHA.112.000712 Clinicians need to identify coronary (...) artery disease patients for whom the benefits of high-dose versus usual-dose statin therapy outweigh potential harm. We therefore aimed to develop and validate a model for prediction of the incremental treatment effect of high-dose statins for individual patients in terms of reduction of 5-year absolute risk for myocardial infarction, stroke, coronary death, or cardiac resuscitation. Based on data from the Treating to New Targets trial (TNT; n=10 001), a Cox proportional hazards model was developed comprising 13 easy

EvidenceUpdates2013

147. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials

Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Fauchier L, Clementy N, Babuty D CRD summary This review concluded that statins reduced the risk of atrial fibrillation (...) in patients with sinus rhythm; the greatest benefit was in prevention of postoperative atrial fibrillation and secondary prevention of atrial fibrillation. Given the variability across studies, limitations of the evidence available, and lack of reporting of the review process, reliability of the review's conclusions is uncertain. Authors' objectives To investigate whether statins can prevent atrial fibrillation. Searching MEDLINE and EMBASE were searched for studies published in English in peer-reviewed

DARE.2013

148. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study.

Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. BACKGROUND: Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4. OBJECTIVE: To measure the frequency of statin toxicity after coprescription of a statin with clarithromycin or erythromycin. DESIGN: Population-based cohort study. SETTING: Ontario, Canada, from 2003 (...) to 2010. PATIENTS: Continuous statin users older than 65 years who were prescribed clarithromycin (n = 72,591) or erythromycin (n = 3267) compared with those prescribed azithromycin (n = 68,478). MEASUREMENTS: The primary outcome was hospitalization with rhabdomyolysis within 30 days of the antibiotic prescription. RESULTS: Atorvastatin was the most commonly prescribed statin (73%) followed by simvastatin and lovastatin. Compared with azithromycin, coprescription of a statin with clarithromycin

Annals of Internal Medicine2013

149. Statin use and risk of pancreatic cancer: a meta-analysis

Statin use and risk of pancreatic cancer: a meta-analysis Statin use and risk of pancreatic cancer: a meta-analysis Statin use and risk of pancreatic cancer: a meta-analysis Cui X, Xie Y, Chen M, Li J, Liao X, Shen J, Shi M, Li W, Zheng H, Jiang B CRD summary This review concluded that there was no substantial evidence for an association between statin use and risk of pancreatic cancer when statins are taken at daily doses for cardiovascular event prevention. Although aspects of this review (...) were well conducted, the reliability of the conclusions are unknown given the limitations of the study data to comprehensively address the review question. Authors' objectives To evaluate the risk of pancreatic cancer as an outcome of statin use. Searching PubMed, BIOSIS Previews, and The Cochrane Library were searched from inception to August 2011 for publications in any language; search terms were provided. A manual search of references of relevant articles and reviews was undertaken. Study

DARE.2013

150. Statin-associated myopathy with normal creatine kinase levels.

Statin-associated myopathy with normal creatine kinase levels. Statin-associated myopathy with n... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2003 ) Volume: 138 , Issue: 12 , Pages: 1007; author reply 1008-1009 Available from or Find this paper at: Abstract BACKGROUND: Muscle symptoms in patients who are treated with statins and have normal creatine kinase levels are not well (...) understood. OBJECTIVE: To report biopsy-confirmed myopathy and normal creatine kinase levels associated with statin use. DESIGN: Case reports from preliminary analysis of an ongoing clinical trial. SETTING: Clinical research center in a community hospital. PATIENTS: Four patients with muscle symptoms that developed during statin therapy and reversed during placebo use. MEASUREMENTS: 1) Patients' ability to identify blinded statin therapy and 2) standard measures of functional capacity and muscle strength

Annals of Internal Medicine2013

151. Meta-analysis: the effect of statins on albuminuria.

Meta-analysis: the effect of statins on albuminuria. Meta-analysis: the effect of stat... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2006 ) Volume: 145 , Issue: 2 , Pages: 117-124 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Albuminuria is an independent risk factor for cardiovascular and renal disease with limited therapeutic options. Data on the effects (...) of statins on albuminuria are conflicting. PURPOSE: To determine whether and to what degree statins affect albuminuria. DATA SOURCES: English-language and non-English-language studies found in PubMed, MEDLINE, EMBASE, BIOSIS, SciSearch, PASCAL, and International Pharmaceutical Abstracts (IPA) databases and the Cochrane Central Register of Controlled Trials that were published between January 1974 and November 2005. STUDY SELECTION: Randomized, placebo-controlled trials of statins reporting baseline

Annals of Internal Medicine2013

152. Annals of Internal Medicine Review Meta-Analysis : The Effect of Statins on Albuminuria

Annals of Internal Medicine Review Meta-Analysis : The Effect of Statins on Albuminuria Annals of Internal Medicine Revie... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2006 ) Volume: 145 , Issue: 2 , Pages: 117-124 Available from or Find this paper at: Abstract Background: Albuminuria is an independent risk factor for cardiovascular and renal disease with limited therapeutic options (...) . Data on the effects of statins on albuminuria are conflicting. Purpose: To determine whether and to what degree statins affect albuminuria. Data Sources: English-language and non-English-language studies found in PubMed, MEDLINE, EMBASE, BIOSIS, SciSearch, PASCAL, and International Pharmaceutical Abstracts (IPA) databases and the Cochrane Central Register of Controlled Trials that were published between January 1974 and November 2005. Study Selection: Randomized, placebo-controlled trials

Annals of Internal Medicine2013

153. Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial.

Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. Association between statin use an... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2009 ) Volume: 150 , Issue: 1 , Pages: 9-18 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Recent evidence suggests that statins may prevent cancer (...) . OBJECTIVE: To quantify the association between statin use and the occurrence of keratinocyte carcinoma in high-risk veterans. DESIGN: Cohort study. SETTING: 6 Veterans Affairs medical centers. PARTICIPANTS: 1037 participants of the Veterans Affairs Topical Tretinoin Chemoprevention Trial, a randomized, multicenter, double-blind, vehicle-controlled trial of topical tretinoin, 0.1%, for prevention of keratinocyte carcinoma conducted from November 1998 to November 2004. MEASUREMENTS: Time to first

Annals of Internal Medicine2013

154. Statin therapy significantly reduces risk of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator

Statin therapy significantly reduces risk of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator Statin therapy significantly reduces risk of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator Statin therapy significantly reduces risk of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator Jacob S, Manickam P, Rathod A, Badheka A, Afonso L, Aravindhakshan R CRD summary The review (...) suggested an association between the use of statins and a reduction in the ventricular tachycardia/ventricular fibrillation occurrence in recipients of implantable cardioverter-defibrillators, mainly in patients with ischaemic cardiomyopathy. The restricted study design reviewed, coupled with significant variation across studies, means the clinical relevance and reliability of the authors' conclusions is uncertain. Authors' objectives To assess whether statin therapy was associated with a decrease

DARE.2013

155. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus

Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus Zhang L, Gong D, Li S, Zhou X CRD summary The review concluded that statins significantly improved the flow-mediated dilatation only in patients with better endothelial functions (...) . Flow-mediated dilatation in evaluating therapeutic outcomes should be used carefully in populations at high risk. The authors' lack of use of their study quality assessment results makes it difficult to evaluate the reliability of their conclusions. Authors' objectives To determine whether statin therapy could improve endothelial dysfunction in patients with diabetes mellitus. Searching PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE were searched to August 2011; search

DARE.2013

156. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials

Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, Robertson M (...) , Wikstrand J, McMurray J CRD summary The evidence did not support the suggestion that statins (or high doses of statins) substantially reduced the risk of venous thromboembolism, but a modest, clinically relevant, reduction in risk, could not be ruled out. There was some uncertainty around the methods, but those that were reported were good. The conclusions reflect the evidence and are likely to be reliable. Authors' objectives To assess the effects of statins on venous thromboembolic events. Searching

DARE.2013

158. Systematic review with meta-analysis: Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events

Systematic review with meta-analysis: Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events Article Text Prevention Systematic review with meta-analysis

Evidence-Based Medicine (Requires free registration)2013

159. Systematic review with meta-analysis: Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis

Systematic review with meta-analysis: Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis Article Text Therapeutics Systematic review with meta-analysis

Evidence-Based Medicine (Requires free registration)2013

160. Randomised controlled trial: Statins induce hyperglycaemia of uncertain importance

Randomised controlled trial: Statins induce hyperglycaemia of uncertain importance Statins induce hyperglycaemia of uncertain importance | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statins induce hyperglycaemia of uncertain importance Article Text Aetiology Randomised controlled trial Statins induce hyperglycaemia of uncertain importance Victor M Montori , Juan P Brito Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Ridker PM , Pradhan A , MacFadyen JG , et al . Cardiovascular benefits and diabetes risks

Evidence-Based Medicine (Requires free registration)2013